243 related articles for article (PubMed ID: 18085428)
1. Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres.
Nerich V; Tissot E; Faradji A; Demesmay K; Bertrand MA; Lorenzini JL; Briquel ME; Pouzol P; Woronoff-Lemsi MC
Pharm World Sci; 2008 Jun; 30(3):287-92. PubMed ID: 18085428
[TBL] [Abstract][Full Text] [Related]
2. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
[TBL] [Abstract][Full Text] [Related]
3. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis for severe haemophilia: clinical and economical issues.
Fischer K; Van Den Berg M
Haemophilia; 2003 Jul; 9(4):376-81. PubMed ID: 12828671
[TBL] [Abstract][Full Text] [Related]
5. Determinants of drug costs in hopitalised patients with haemophilia: impact of recombinant activated factor VII.
Galanaud JP; Pelletier-Fleury N; Logerot-Lebrun H; Lambert T
Pharmacoeconomics; 2003; 21(10):699-707. PubMed ID: 12828492
[TBL] [Abstract][Full Text] [Related]
6. Epidemiological survey of haemophiliacs with inhibitors in France: orthopaedic status, quality of life and cost--the 'Statut Orthopédique des Patients Hémophiles' avec Inhibiteur study.
Stieltjes N; Torchet MF; Misrahi L; Roussel-Robert V; Lambert T; Guérois C; Bertrand MA; Briquel ME; Borel-Derlon A; Dirat G
Blood Coagul Fibrinolysis; 2009 Jan; 20(1):4-11. PubMed ID: 20527720
[TBL] [Abstract][Full Text] [Related]
7. The natural history of mild haemophilia: a 30-year single centre experience.
Tagliaferri A; Di Perna C; Riccardi F; Pattacini C; Rivolta GF; Franchini M
Haemophilia; 2012 Mar; 18(2):166-74. PubMed ID: 21771207
[TBL] [Abstract][Full Text] [Related]
8. Recombinant clotting factors in the treatment of hemophilia.
Lee C
Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
[No Abstract] [Full Text] [Related]
9. Participation in research: the economic advantages in a haemophilia research population.
Wasserman J; Ullman M; Cantini M; Moynihan K; Hoots WK
Haemophilia; 2000 Sep; 6(5):571-4. PubMed ID: 11012704
[No Abstract] [Full Text] [Related]
10. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS).
Globe DR; Curtis RG; Koerper MA;
Haemophilia; 2004 Mar; 10 Suppl 1():63-70. PubMed ID: 14987251
[TBL] [Abstract][Full Text] [Related]
11. The overall effectiveness of prophylaxis in severe haemophilia.
Panicker J; Warrier I; Thomas R; Lusher JM
Haemophilia; 2003 May; 9(3):272-8. PubMed ID: 12694517
[TBL] [Abstract][Full Text] [Related]
12. Variability of treatment modalities and intensity in patients with severe haemophilia A on prophylaxis: Results from the Italian national registry.
Cortesi PA; Giampaolo A; Abbonizio F; Molinari AC; Castaman G; Biffoni M; Mantovani LG
Eur J Haematol; 2021 Oct; 107(4):408-415. PubMed ID: 34110639
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy.
Abbonizio F; Giampaolo A; Coppola A; ; Arcieri R; Hassan HJ
Haemophilia; 2014 Jul; 20(4):e243-50. PubMed ID: 24834967
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors.
Pochopien M; Tytuła A; Toumi M; Falk A; Martone N; Hakimi Z; Eriksson D
Adv Ther; 2024 Jun; 41(6):2307-2323. PubMed ID: 38652439
[TBL] [Abstract][Full Text] [Related]
15. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Scharrer I
Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany.
Auerswald G; von Depka Prondzinski M; Ehlken B; Kreuz W; Kurnik K; Lenk H; Scharrer I; Schramm W; Zimmermann R
Haemophilia; 2004 Sep; 10(5):499-508. PubMed ID: 15357777
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
Epstein J; Xiong Y; Woo P; Li-McLeod J; Spotts G
Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
[TBL] [Abstract][Full Text] [Related]
18. The economic impact of factor VIII inhibitors in patients with haemophilia.
Bohn RL; Aledort LM; Putnam KG; Ewenstein BM; Mogun H; Avorn J
Haemophilia; 2004 Jan; 10(1):63-8. PubMed ID: 14962222
[TBL] [Abstract][Full Text] [Related]
19. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
Wang C; Young G
Haemophilia; 2018 May; 24(3):414-419. PubMed ID: 29405496
[TBL] [Abstract][Full Text] [Related]
20. Haemophilia A: health and economic burden of a rare disease in Portugal.
Café A; Carvalho M; Crato M; Faria M; Kjollerstrom P; Oliveira C; Pinto PR; Salvado R; Dos Santos AA; Silva C
Orphanet J Rare Dis; 2019 Sep; 14(1):211. PubMed ID: 31484564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
